Beijing: Having been in the Chinese pharmaceutical market for 30 years, Japan’s Takeda Pharmaceutical Co Ltd is optimistic about the market and will keep investing in the country, a senior company executive says.
“China is a key strategic market for Takeda. This year marks the 30th anniversary of Takeda in China, which is a significant milestone demonstrating our long-term commitment to China,” said Thomas Wozniewski, global manufacturing and supply officer at Takeda.
“China is Takeda’s third-largest market. Our China business maintained strong growth which has been exceeding market growth since 2020. It is expected that China will become our second-largest market by 2031,” Wozniewski said.
Between 2020 and 2024, Takeda brought 16 medicines and treatment options to the Chinese market.
“The Chinese government is increasingly recognising the value of innovative medicines and has established pathways, for example, the ‘breakthrough-therapy’ designation, to accelerate the registration process. Thanks to this initiative, Takeda in China has successfully obtained breakthrough designations for several new assets,” Wozniewski said.
Since China’s medical reform in 2015, the development of innovative drugs in the country has greatly accelerated pace.
The approval time of such drugs has been cut from 16 months to around 50 days, and that of urgent clinical drugs has been cut even shorter, creating favourable conditions for the development of innovative drugs. — China Daily/ANN
